Loading stock data…
Immunome, Inc. (IMNM)
$26.96+0.20 (+0.75%)
Market OpenUpdated 9:47 AM EDT
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunome, Inc. in the Healthcare sector is trading at $26.81 with a market capitalization of $3.1B. Wall Street consensus targets $36.31 (13 analysts), implying a +35.4% move over the next 12 months. The stock is currently near its 52-week high of $30.06, remaining 19.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $4.01M↑ | $2.93M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$59.33M↑ | -$72.86M↓ | -$60.14M↓ | -$46.48M↓ | -$44.64M |
| Net Income | -$53.84M↑ | -$69.90M↓ | -$57.46M↓ | -$43.40M↓ | -$41.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.43%
Volume
Today's trading volume
52,499
Recent News
What This Immunome Sale Means a Day Before a Big FDA Milestone
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
Immunome Stock Up 32% in a Month: Here's What You Should Know
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?
Immunome, Inc. recently reported detailed efficacy and safety results from its global Phase 3 RINGSIDE trial of varegacestat in progressing desmoid tumors, showing statistically significant benefits in progression-free survival and pain reduction, and has already submitted a New Drug Application to the US FDA with an EU filing planned. An interesting aspect for investors is that the progression-free survival benefit appeared consistent across multiple prespecified patient subgroups, hinting...
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.